Q-omics provides the consensus-scored LEMD1 profile across patient tissues and cancer cell-line models. LEMD1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LEMD1 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, LEMD1 RNA expression shows 13,479 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRP, COAD, and BRCA as cancer lineages where LEMD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LEMD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LEMD1 survival associations across molecular data types. LEMD1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LEMD1 RNA expression–survival associations across cancer types. High LEMD1 expression shows unfavorable associations in KIRP, KIRC, READ and PAAD, but favorable associations in OV and STAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LEMD1 RNA expression.
This table summarizes LEMD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LEMD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LEMD1 shows lower tumor expression in KICH and higher tumor expression in COAD, HNSC, THCA, LUAD and KIRP. The COAD box plot shows higher LEMD1 RNA expression in tumor versus normal tissue (log2 FC = +3.044, t-test p < 0.001).
This table shows molecular features associated with LEMD1 in patient tissues and cancer cell lines. In patient samples, LEMD1 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, LEMD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LUNG_SCLC.
